MD20150035A2 - Inhibitori de tirozinkinaza Bruton - Google Patents
Inhibitori de tirozinkinaza Bruton Download PDFInfo
- Publication number
- MD20150035A2 MD20150035A2 MDA20150035A MD20150035A MD20150035A2 MD 20150035 A2 MD20150035 A2 MD 20150035A2 MD A20150035 A MDA20150035 A MD A20150035A MD 20150035 A MD20150035 A MD 20150035A MD 20150035 A2 MD20150035 A2 MD 20150035A2
- Authority
- MD
- Moldova
- Prior art keywords
- bruton
- tyrosine kinase
- compounds
- disclosed
- conditions
- Prior art date
Links
- 102000001714 Agammaglobulinaemia Tyrosine Kinase Human genes 0.000 title abstract 3
- 108010029445 Agammaglobulinaemia Tyrosine Kinase Proteins 0.000 title abstract 3
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 title 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 229940124291 BTK inhibitor Drugs 0.000 abstract 1
- 206010025323 Lymphomas Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epidemiology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261721920P | 2012-11-02 | 2012-11-02 | |
| US201361772028P | 2013-03-04 | 2013-03-04 | |
| PCT/IB2013/059846 WO2014068527A1 (en) | 2012-11-02 | 2013-11-01 | Bruton's tyrosine kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MD20150035A2 true MD20150035A2 (ro) | 2015-10-31 |
Family
ID=49596360
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MDA20150035A MD20150035A2 (ro) | 2012-11-02 | 2013-11-01 | Inhibitori de tirozinkinaza Bruton |
Country Status (27)
| Country | Link |
|---|---|
| US (4) | US20150291554A1 (enExample) |
| EP (1) | EP2914586B1 (enExample) |
| JP (1) | JP6178861B2 (enExample) |
| KR (1) | KR101668574B1 (enExample) |
| CN (1) | CN105008344B (enExample) |
| AP (1) | AP2015008381A0 (enExample) |
| AU (1) | AU2013340345B2 (enExample) |
| BR (1) | BR112015009624A2 (enExample) |
| CA (1) | CA2888960C (enExample) |
| CL (1) | CL2015001168A1 (enExample) |
| CO (1) | CO7350624A2 (enExample) |
| CR (1) | CR20150228A (enExample) |
| DO (1) | DOP2015000100A (enExample) |
| EA (1) | EA201500393A1 (enExample) |
| ES (1) | ES2625944T3 (enExample) |
| GE (1) | GEP201606597B (enExample) |
| HK (1) | HK1211293A1 (enExample) |
| IL (1) | IL238571A0 (enExample) |
| MD (1) | MD20150035A2 (enExample) |
| MX (1) | MX2015005422A (enExample) |
| NI (1) | NI201500059A (enExample) |
| PE (1) | PE20151070A1 (enExample) |
| PH (1) | PH12015500940A1 (enExample) |
| SG (1) | SG11201502893WA (enExample) |
| TN (1) | TN2015000168A1 (enExample) |
| TW (1) | TWI518080B (enExample) |
| WO (1) | WO2014068527A1 (enExample) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201500499TA (en) | 2012-08-10 | 2015-03-30 | Boehringer Ingelheim Int | Heteroaromatic compounds as bruton's tyrosine kinase (btk) inhibitors |
| SI2892900T1 (en) | 2012-09-10 | 2018-01-31 | Principia Biopharma Inc. | Pyrazolopyrimidine compounds as kinase inhibitors |
| CN103848810A (zh) | 2012-11-30 | 2014-06-11 | 北京赛林泰医药技术有限公司 | 鲁顿酪氨酸激酶抑制剂 |
| JP6403751B2 (ja) | 2013-03-14 | 2018-10-10 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ５−チアゾールカルボキサミン誘導体及びｂｔｋ阻害剤としてのその使用 |
| JP6495886B2 (ja) | 2013-03-15 | 2019-04-03 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｂｔｋ阻害剤としての複素環式芳香族化合物 |
| US9156847B2 (en) * | 2013-03-15 | 2015-10-13 | Janssen Pharmaceutica Nv | Processes and intermediates for preparing a medicament |
| CA2901510C (en) * | 2013-03-15 | 2022-11-29 | Janssen Pharmaceutica Nv | Processes for preparing ibrutinib derivatives and intermediates thereof |
| CN113413393B (zh) * | 2013-08-19 | 2025-03-04 | 塔里斯生物医药公司 | 多单元药物递送装置和方法 |
| KR102272792B1 (ko) | 2013-09-30 | 2021-07-05 | 광저우 이노케어 파마 테크 씨오., 엘티디. | Ｂｔｋ의 치환된 니코틴이미드 저해제 및 그의 제조 방법 및 암, 염증 및 자가면역 질환에의 용도 |
| JP6486954B2 (ja) * | 2014-01-29 | 2019-03-20 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｂｔｋ阻害剤としてのピラゾール化合物 |
| CN112353806A (zh) | 2014-02-21 | 2021-02-12 | 普林斯匹亚生物制药公司 | Btk抑制剂的盐和固体形式 |
| WO2015185998A2 (en) * | 2014-04-11 | 2015-12-10 | Acerta Pharma B.V. | Methods of blocking the cxcr-4/sdf-1 signaling pathway with inhibitors of bone marrow x kinase |
| CN105085474B (zh) | 2014-05-07 | 2018-05-18 | 北京赛林泰医药技术有限公司 | 鲁顿酪氨酸激酶抑制剂 |
| GB201410430D0 (en) | 2014-06-11 | 2014-07-23 | Redx Pharma Ltd | Compounds |
| CN106687446B (zh) * | 2014-07-18 | 2020-04-28 | 百济神州(北京)生物科技有限公司 | 作为t790m/wt-egfr的选择性和不可逆的激酶抑制剂的5-氨基-4-氨甲酰基-吡唑化合物及其用途 |
| WO2016019237A2 (en) * | 2014-07-31 | 2016-02-04 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
| CN105884747B (zh) * | 2014-08-28 | 2021-01-05 | 首药控股(北京)有限公司 | 一种制备布鲁顿酪氨酸激酶(btk)激酶抑制剂的制备方法 |
| SG11201704808VA (en) | 2014-12-18 | 2017-07-28 | Principia Biopharma Inc | Treatment of pemphigus |
| WO2016192074A1 (en) * | 2015-06-04 | 2016-12-08 | Merck Sharp & Dohme Corp. | Btk inhibitors |
| WO2016210165A1 (en) | 2015-06-24 | 2016-12-29 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
| JP7337502B2 (ja) | 2015-09-16 | 2023-09-04 | ロクソ オンコロジー， インコーポレイテッド | がんの治療のためのｂｔｋ阻害剤としてのピラゾロピリミジン誘導体 |
| SI3377484T1 (sl) * | 2015-11-17 | 2024-02-29 | Merck Patent Gmbh | Postopki za zdravljenje multiple skleroze z uporabo pirimidinskih in piridinskih spojin z btk inhibitorno aktivnostjo |
| LT3390390T (lt) | 2015-12-16 | 2021-11-25 | Boehringer Ingelheim International Gmbh | Bipirazolilo dariniai, tinkami naudoti autoimuninių ligų gydymui |
| CN114716381B (zh) * | 2015-12-16 | 2025-03-11 | 洛克索肿瘤学股份有限公司 | 可用作激酶抑制剂的化合物 |
| US10570118B2 (en) | 2016-01-13 | 2020-02-25 | Boehringer Ingelheim International Gmbh | Isoquinolones as BTK inhibitors |
| CN107021963A (zh) | 2016-01-29 | 2017-08-08 | 北京诺诚健华医药科技有限公司 | 吡唑稠环类衍生物、其制备方法及其在治疗癌症、炎症和免疫性疾病上的应用 |
| CN108884068B (zh) | 2016-03-24 | 2021-02-26 | 特殊治疗有限公司 | 作为dub抑制剂的1-氰基-吡咯烷衍生物 |
| KR102404759B1 (ko) * | 2016-05-16 | 2022-05-31 | 쑤저우 시노벤트 파마슈티칼즈 씨오., 엘티디. | Ｂｔｋ 억제제로서의 5-아미노피라졸 카르복사미드 유도체 및 그것의 제조 방법 및 제약학적 조성물 |
| CN115054586B (zh) | 2016-06-29 | 2024-08-02 | 普林斯匹亚生物制药公司 | 改性的释放制剂 |
| GB201616511D0 (en) | 2016-09-29 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
| GB201616627D0 (en) | 2016-09-30 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
| TWI771327B (zh) * | 2016-10-05 | 2022-07-21 | 英商使命醫療公司 | 新穎化合物 |
| CA3045339A1 (en) | 2016-12-03 | 2018-06-07 | Juno Therapeutics, Inc. | Methods and compositions for use of therapeutic t cells in combination with kinase inhibitors |
| WO2018119142A1 (en) | 2016-12-21 | 2018-06-28 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| AU2018346597B2 (en) | 2017-10-06 | 2023-07-13 | Forma Therapeutics, Inc. | Inhibiting Ubiquitin Specific Peptidase 30 |
| WO2019091438A1 (zh) * | 2017-11-10 | 2019-05-16 | 苏州信诺维医药科技有限公司 | 作为btk抑制剂的5-氨基吡唑甲酰胺化合物的无定型固体分散体 |
| US11180475B2 (en) | 2017-11-10 | 2021-11-23 | Sinomab Bioscience Limited | Crystal form I of a 5-aminopyrazole carboxamide compound as BTK inhibitor |
| CN111225912B (zh) * | 2017-11-10 | 2020-11-10 | 苏州信诺维医药科技有限公司 | 作为btk抑制剂的5-氨基吡唑甲酰胺化合物及其制备方法 |
| JP7449242B2 (ja) | 2018-05-17 | 2024-03-13 | フォーマ セラピューティクス，インコーポレイテッド | ユビキチン特異的ペプチダーゼ３０（ｕｓｐ３０）阻害剤として有用な縮合二環化合物 |
| CN108530436B (zh) * | 2018-05-17 | 2020-12-29 | 黄传满 | 一种吡唑类化合物及其制备方法和应用 |
| JP7530889B2 (ja) | 2018-10-05 | 2024-08-08 | フォーマ セラピューティクス，インコーポレイテッド | ユビキチン特異的プロテアーゼ３０（ｕｓｐ３０）阻害剤として作用する縮合ピロリン |
| IL286373B2 (en) * | 2019-03-14 | 2026-03-01 | Calico Life Sciences Llc | Protein tyrosine phosphate inhibitor compounds and uses thereof |
| EA202192575A1 (ru) | 2019-03-21 | 2022-01-14 | Онксео | Соединения dbait в сочетании с ингибиторами киназ для лечения рака |
| KR20220011669A (ko) * | 2019-05-21 | 2022-01-28 | 얀센 파마슈티카 엔.브이. | Btk 억제제 제조를 위한 방법 및 중간체 |
| US20210106584A1 (en) | 2019-10-14 | 2021-04-15 | Principia Biopharma Inc. | Methods for treating immune thrombocytopenia by administering (r)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile |
| CN114761006A (zh) | 2019-11-08 | 2022-07-15 | Inserm(法国国家健康医学研究院) | 对激酶抑制剂产生耐药性的癌症的治疗方法 |
| JP7142173B2 (ja) | 2019-12-06 | 2022-09-26 | ロクソ オンコロジー， インコーポレイテッド | ブルトン型チロシンキナーゼ阻害剤の投薬 |
| US11814390B2 (en) | 2020-01-22 | 2023-11-14 | Principia Biopharma Inc. | Crystalline forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)-1H-pyrazolo[3,4-D]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| TW202317099A (zh) * | 2020-09-10 | 2023-05-01 | 美商絡速藥業公司 | 用於製備(s)-5-胺基-3-(4-((5-氟-2-甲氧基苯甲醯胺基)甲基)苯基)-1-(1,1,1-三氟丙烷-2-基)-1h-吡唑-4-甲醯胺之方法及中間體 |
| MX2023002953A (es) * | 2020-09-11 | 2023-06-01 | Calico Life Sciences Llc | Inhibidores de proteína tirosina fosfatasa y métodos para su uso. |
| US20240100172A1 (en) | 2020-12-21 | 2024-03-28 | Hangzhou Jijing Pharmaceutical Technology Limited | Methods and compounds for targeted autophagy |
| CN115611810B (zh) * | 2021-07-16 | 2025-03-04 | 深圳市塔吉瑞生物医药有限公司 | 取代的吡唑类化合物及包含该化合物的组合物及其用途 |
| CN116554102B (zh) * | 2022-01-28 | 2025-10-03 | 深圳海博为药业有限公司 | 一种作为btk抑制剂的化合物及其制备方法和应用 |
| WO2023150663A1 (en) * | 2022-02-04 | 2023-08-10 | Retune Pharma Inc. | Certain chemical entities, compositions, and methods |
| CN120569391A (zh) * | 2023-01-19 | 2025-08-29 | 北京普祺医药科技股份有限公司 | 一种吡唑并环类化合物、药物组合物及其用途 |
| WO2024153237A1 (zh) * | 2023-01-19 | 2024-07-25 | 北京普祺医药科技股份有限公司 | 一种igf-1r酪氨酸激酶抑制剂、药物组合物及其用途 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
| US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| US6326469B1 (en) | 1994-04-22 | 2001-12-04 | Sugen, Inc. | Megakaryocytic protein tyrosine kinases |
| GB9608435D0 (en) * | 1996-04-24 | 1996-06-26 | Celltech Therapeutics Ltd | Chemical compounds |
| EP1436265A4 (en) * | 2001-09-27 | 2004-12-15 | Smithkline Beecham Corp | CHEMICALS |
| CA2648923A1 (en) | 2006-04-11 | 2007-10-18 | Vertex Pharmaceuticals Incorporated | Thiazoles, imidazoles, and pyrazoles useful as inhibitors of protein kinases |
| DK2526933T3 (en) * | 2006-09-22 | 2015-05-18 | Pharmacyclics Inc | Inhibitors of Bruton's tyrosine kinase |
| FR2908409B1 (fr) | 2006-11-10 | 2009-01-09 | Sanofi Aventis Sa | Pyrazoles substituees,compositions les contenant,procede de fabrication et utilisation |
| EP2173728A2 (en) * | 2007-07-17 | 2010-04-14 | Amgen Inc. | Heterocyclic modulators of pkb |
| CA2730930C (en) * | 2008-07-16 | 2015-01-13 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors |
| PT2324008E (pt) | 2008-07-24 | 2012-06-25 | Nerviano Medical Sciences Srl | 3,4-diarilpirazoles como inibidores da proteína quinase |
| NZ598985A (en) * | 2009-09-04 | 2013-07-26 | Biogen Idec Inc | Bruton's tyrosine kinase inhibitors |
| WO2011159857A1 (en) * | 2010-06-16 | 2011-12-22 | Bristol-Myers Squibb Company | Carboline carboxamide compounds useful as kinase inhibitors |
| SG11201500499TA (en) * | 2012-08-10 | 2015-03-30 | Boehringer Ingelheim Int | Heteroaromatic compounds as bruton's tyrosine kinase (btk) inhibitors |
| CN103848810A (zh) * | 2012-11-30 | 2014-06-11 | 北京赛林泰医药技术有限公司 | 鲁顿酪氨酸激酶抑制剂 |
| FR3002733B1 (fr) | 2013-03-04 | 2015-08-14 | Servier Lab | Nouveau sel de l'abexinostat, forme cristalline associee,leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| US10105632B2 (en) | 2014-04-09 | 2018-10-23 | Donaldson Company, Inc. | Self-supporting folded sheet material, filter elements, and methods |
| CN105085474B (zh) * | 2014-05-07 | 2018-05-18 | 北京赛林泰医药技术有限公司 | 鲁顿酪氨酸激酶抑制剂 |
-
2013
- 2013-11-01 KR KR1020157014092A patent/KR101668574B1/ko not_active Expired - Fee Related
- 2013-11-01 MX MX2015005422A patent/MX2015005422A/es unknown
- 2013-11-01 SG SG11201502893WA patent/SG11201502893WA/en unknown
- 2013-11-01 HK HK15112141.6A patent/HK1211293A1/xx unknown
- 2013-11-01 AU AU2013340345A patent/AU2013340345B2/en not_active Ceased
- 2013-11-01 US US14/439,478 patent/US20150291554A1/en not_active Abandoned
- 2013-11-01 AP AP2015008381A patent/AP2015008381A0/xx unknown
- 2013-11-01 CN CN201380065731.8A patent/CN105008344B/zh not_active Expired - Fee Related
- 2013-11-01 BR BR112015009624A patent/BR112015009624A2/pt active Search and Examination
- 2013-11-01 CA CA2888960A patent/CA2888960C/en not_active Expired - Fee Related
- 2013-11-01 JP JP2015540256A patent/JP6178861B2/ja not_active Expired - Fee Related
- 2013-11-01 ES ES13792494.0T patent/ES2625944T3/es active Active
- 2013-11-01 WO PCT/IB2013/059846 patent/WO2014068527A1/en not_active Ceased
- 2013-11-01 EP EP13792494.0A patent/EP2914586B1/en active Active
- 2013-11-01 GE GEAP201313816A patent/GEP201606597B/en unknown
- 2013-11-01 MD MDA20150035A patent/MD20150035A2/ro not_active Application Discontinuation
- 2013-11-01 PE PE2015000569A patent/PE20151070A1/es not_active Application Discontinuation
- 2013-11-01 EA EA201500393A patent/EA201500393A1/ru unknown
- 2013-11-04 TW TW102139984A patent/TWI518080B/zh not_active IP Right Cessation
-
2015
- 2015-04-27 PH PH12015500940A patent/PH12015500940A1/en unknown
- 2015-04-29 CO CO15098489A patent/CO7350624A2/es unknown
- 2015-04-30 NI NI201500059A patent/NI201500059A/es unknown
- 2015-04-30 IL IL238571A patent/IL238571A0/en unknown
- 2015-04-30 TN TNP2015000168A patent/TN2015000168A1/fr unknown
- 2015-04-30 CR CR20150228A patent/CR20150228A/es unknown
- 2015-05-01 DO DO2015000100A patent/DOP2015000100A/es unknown
- 2015-05-04 CL CL2015001168A patent/CL2015001168A1/es unknown
-
2017
- 2017-06-16 US US15/624,969 patent/US10266513B2/en active Active
-
2019
- 2019-03-08 US US16/296,319 patent/US10815213B2/en active Active
-
2020
- 2020-09-18 US US17/025,026 patent/US20210002251A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MD20150035A2 (ro) | Inhibitori de tirozinkinaza Bruton | |
| PH12015501067A1 (en) | Pyrrolopyrimidine compounds as kinase inhibitors | |
| PH12014501815A1 (en) | Purinone compounds as kinase inhibitors | |
| PH12016500575A1 (en) | Inhibitors of bruton`s tyrosine kinase | |
| NZ700928A (en) | Dna-pk inhibitors | |
| MX2013011908A (es) | Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank. | |
| IN2012MN02591A (enExample) | ||
| IN2014MN02069A (enExample) | ||
| MX2020010535A (es) | Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide. | |
| UA115558C2 (uk) | Алкілпіримідинові похідні для лікування вірусних інфекцій та подальших захворювань | |
| SG10201808102WA (en) | Bicyclic heterocycle compounds and their uses in therapy | |
| IN2014MN00986A (enExample) | ||
| MX349004B (es) | Nuevos compuestos. | |
| PH12015500713B1 (en) | Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases | |
| MX2014000964A (es) | Derivados aza heterociclicos sustituidos. | |
| TW201613926A (en) | Inhibitors of bruton's tyrosine kinase | |
| UA110910C2 (uk) | Карбоксамідні похідні піразолу як інгібітори тирозинкінази брутона, фармацевтична композиція на їх основі та спосіб лікування захворювань (варіанти) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HK9A | Erratum in official gazette with regard to application (patent for invention) |
Free format text: RECTIFICATION IN INID 72 |
|
| FA9A | Abandonment or withdrawal of application (patent for invention) |